Literature DB >> 27758823

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

Kevin Rouault-Pierre1, Alexander E Smith2,3, Syed A Mian1,3, Irene Pizzitola1, Austin G Kulasekararaj2,3, Ghulam J Mufti4,3, Dominique Bonnet5.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27758823      PMCID： PMC5210239          DOI： 10.3324/haematol.2016.152520

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Genetics factors associated with myelodysplastic syndromes.

Authors:  Luciana Conci Macedo; Ana Paula Avenia Silvestre; Camila Rodrigues; Josiane Bazzo de Alencar; Joana Maira Valentini Zacarias; Eliane Papa Ambrosio-Albuquerque; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Blood Cells Mol Dis       Date:  2015-04-17       Impact factor: 3.039

2.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

3.  ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; Julien Roquain; José Adélaïde; Nadine Carbuccia; Benjamin Esterni; Pascal Finetti; Anne Murati; Christine Arnoulet; Hacène Zerazhi; Hacène Fezoui; Zoulika Tadrist; Meyer Nezri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

Review 4.  Xenograft models for normal and malignant stem cells.

Authors:  Susumu Goyama; Mark Wunderlich; James C Mulloy
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113

5.  MDS is a stem cell disorder after all.

Authors:  Siddhartha Jaiswal; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

6.  Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.

Authors:  Lars Nilsson; Ingbritt Astrand-Grundström; Kristina Anderson; Ingrid Arvidsson; Peter Hokland; David Bryder; Lars Kjeldsen; Bertil Johansson; Eva Hellström-Lindberg; Robert Hast; Sten Eirik W Jacobsen
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

7.  Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

Authors:  Hind Medyouf; Maximilian Mossner; Johann-Christoph Jann; Florian Nolte; Simon Raffel; Carl Herrmann; Amelie Lier; Christian Eisen; Verena Nowak; Bettina Zens; Katja Müdder; Corinna Klein; Julia Obländer; Stephanie Fey; Jovita Vogler; Alice Fabarius; Eva Riedl; Henning Roehl; Alexander Kohlmann; Marita Staller; Claudia Haferlach; Nadine Müller; Thilo John; Uwe Platzbecker; Georgia Metzgeroth; Wolf-Karsten Hofmann; Andreas Trumpp; Daniel Nowak
Journal:  Cell Stem Cell       Date:  2014-04-03       Impact factor: 24.633

8.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Authors:  Maximilian Mossner; Johann-Christoph Jann; Janina Wittig; Florian Nolte; Stephanie Fey; Verena Nowak; Julia Obländer; Jovita Pressler; Iris Palme; Christina Xanthopoulos; Tobias Boch; Georgia Metzgeroth; Henning Röhl; Stephanie H Witt; Helene Dukal; Corinna Klein; Steffen Schmitt; Patrick Gelß; Uwe Platzbecker; Ekaterina Balaian; Alice Fabarius; Helmut Blum; Torsten J Schulze; Manja Meggendorfer; Claudia Haferlach; Andreas Trumpp; Wolf-Karsten Hofmann; Hind Medyouf; Daniel Nowak
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

9.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Authors:  Petter S Woll; Una Kjällquist; Onima Chowdhury; Helen Doolittle; David C Wedge; Supat Thongjuea; Rikard Erlandsson; Mtakai Ngara; Kristina Anderson; Qiaolin Deng; Adam J Mead; Laura Stenson; Alice Giustacchini; Sara Duarte; Eleni Giannoulatou; Stephen Taylor; Mohsen Karimi; Christian Scharenberg; Teresa Mortera-Blanco; Iain C Macaulay; Sally-Ann Clark; Ingunn Dybedal; Dag Josefsen; Pierre Fenaux; Peter Hokland; Mette S Holm; Mario Cazzola; Luca Malcovati; Sudhir Tauro; David Bowen; Jacqueline Boultwood; Andrea Pellagatti; John E Pimanda; Ashwin Unnikrishnan; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Magnus Tobiasson; Gunnar Kvalheim; Stefan N Constantinescu; Claus Nerlov; Lars Nilsson; Peter J Campbell; Rickard Sandberg; Elli Papaemmanuil; Eva Hellström-Lindberg; Sten Linnarsson; Sten Eirik W Jacobsen
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

10.  SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.

Authors:  Syed A Mian; Kevin Rouault-Pierre; Alexander E Smith; Thomas Seidl; Irene Pizzitola; Aytug Kizilors; Austin G Kulasekararaj; Dominique Bonnet; Ghulam J Mufti
Journal:  Nat Commun       Date:  2015-12-08       Impact factor: 14.919
  10 in total
  8 in total

Review 1.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

2.  NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Authors:  Emmanuel Griessinger; Michael Andreeff
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

3.  Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells.

Authors:  Bingqing Luo; Fang Dong; Tiejun Qin; Qingyun Zhang; Haitao Bai; Jinhong Wang; Yujiao Jia; Shihui Ma; Erlie Jiang; Tao Cheng; Zhijian Xiao; Hideo Ema
Journal:  Exp Hematol Oncol       Date:  2022-05-16

4.  Preclinical modeling of myelodysplastic syndromes.

Authors:  K Rouault-Pierre; S A Mian; M Goulard; A Abarrategi; A Di Tulio; A E Smith; A Mohamedali; S Best; A-M Nloga; A G Kulasekararaj; L Ades; C Chomienne; P Fenaux; C Dosquet; G J Mufti; D Bonnet
Journal:  Leukemia       Date:  2017-06-02       Impact factor: 11.528

5.  Acute myeloid leukemia xenograft success prediction: Saving time.

Authors:  Emmanuel Griessinger; Jacques Vargaftig; Stuart Horswell; David C Taussig; John Gribben; Dominique Bonnet
Journal:  Exp Hematol       Date:  2017-12-15       Impact factor: 3.084

6.  Engraftment characterization of risk-stratified AML in NSGS mice.

Authors:  Rafael Díaz de la Guardia; Talía Velasco-Hernandez; Francisco Gutiérrez-Agüera; Heleia Roca-Ho; Oscar Molina; Cesar Nombela-Arrieta; Alex Bataller; Jose Luis Fuster; Eduardo Anguita; Susana Vives; Lurdes Zamora; Josep Nomdedeu; María Teresa Gómez-Casares; Manuel Ramírez-Orellana; Helene Lapillonne; Verónica Ramos-Mejia; Juan Carlos Rodríguez-Manzaneque; Clara Bueno; Belen Lopez-Millan; Pablo Menéndez
Journal:  Blood Adv       Date:  2021-12-14

Review 7.  Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.

Authors:  Ander Abarrategi; Syed A Mian; Diana Passaro; Kevin Rouault-Pierre; William Grey; Dominique Bonnet
Journal:  J Exp Med       Date:  2018-02-16       Impact factor: 14.307

8.  Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

Authors:  Marie Bill; Peter B van Kooten Niekerk; Petter S Woll; Laura Laine Herborg; Anne Stidsholt Roug; Peter Hokland; Line Nederby
Journal:  J Cell Mol Med       Date:  2018-02-07       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.